The chemical class of Serine racemase activators presents a rich array of compounds that intricately modulate the activity of Serine racemase, a pivotal enzyme involved in the process of serine racemization. This diverse group of activators can be broadly categorized into two main classes based on their mechanisms of action, offering researchers a multifaceted toolkit for studying and manipulating Serine racemase activity within cellular contexts. The first category comprises direct agonists of the NMDA receptor, including D-cycloserine, NMDA, and D-Serine. These compounds act as initiators of calcium influx, positively influencing Serine racemase activity through the activation of the N-methyl-D-aspartate (NMDA) receptor. The resulting cascade of events, triggered by calcium influx, plays a crucial role in enhancing the enzymatic activity of Serine racemase. This direct modulation represents a cornerstone in understanding the intricate regulatory mechanisms governing serine racemization processes.
In contrast, the second category includes compounds such as A769662 and Aniracetam, which indirectly activate Serine racemase by targeting distinct cellular pathways. A769662 operates through the AMP-activated protein kinase (AMPK) pathway, while Aniracetam influences the AMPA receptor pathway, both leading to increased intracellular calcium levels. This indirect activation underscores the interconnected nature of cellular signaling pathways and their impact on Serine racemase activity. Moreover, inhibitors targeting negative regulators, such as Rapamycin and KN-62, which act on the mTOR and CaMKII pathways, respectively, contribute to enhanced Serine racemase activation. By negating the inhibitory effects imposed by these pathways, these compounds unravel the intricate interplay between regulatory mechanisms and Serine racemase. This nuanced understanding of activators and inhibitors provides researchers with a powerful toolkit to decipher the complex network of biochemical and cellular pathways influenced by Serine racemase, thereby advancing our comprehension of serine racemization processes and their broader implications in cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PI 3-Kγ Inhibitor | 648450-29-7 | sc-203191 | 5 mg | $76.00 | ||
AS605240 (PI 3-Kγ Inhibitor) indirectly activates IRS-4 by inhibiting PI3Kγ, which negatively regulates IRS-4. Inhibition of PI3Kγ by AS605240 leads to increased IRS-4 activation, supporting its cellular functions within the insulin signaling pathway. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
An mTORC1 and mTORC2 inhibitor. Palomid 529 indirectly activates IRS-4 by inhibiting mTORC1 and mTORC2, which negatively regulate IRS-4. Inhibition of mTORC1 and mTORC2 by Palomid 529 leads to increased IRS-4 activation, supporting its cellular functions within the insulin signaling pathway. | ||||||
BMS-536924 | 468740-43-4 | sc-507397 | 5 mg | $285.00 | ||
A dual inhibitor of IGF-1R and insulin receptor. BMS-536924 indirectly activates IRS-4 by inhibiting IGF-1R and insulin receptor, which negatively regulate IRS-4. Inhibition of these receptors by BMS-536924 leads to increased IRS-4 activation, supporting its cellular functions within the insulin signaling pathway. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
A potent inhibitor of PI3Kα and PI3Kδ. Pictilisib indirectly activates IRS-4 by inhibiting PI3Kα and PI3Kδ, which negatively regulate IRS-4. Inhibition of these PI3K isoforms by Pictilisib leads to increased IRS-4 activation, supporting its cellular functions within the insulin signaling pathway. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
A small molecule inhibitor of STAT3. Stattic indirectly activates IRS-4 by blocking the inhibitory effects of STAT3. IRS-4 is negatively regulated by STAT3, and Stattic's inhibition of STAT3 leads to increased IRS-4 activation, supporting its cellular functions within the insulin signaling pathway. | ||||||
A66 | 1166227-08-2 | sc-364394 sc-364394A | 5 mg 50 mg | $255.00 $1455.00 | ||
A selective inhibitor of mTORC1 and mTORC2. A66 indirectly activates IRS-4 by inhibiting mTORC1 and mTORC2, which negatively regulate IRS-4. Inhibition of these mTOR complexes by A66 leads to increased IRS-4 activation, supporting its cellular functions within the insulin signaling pathway. | ||||||